Sarah Larson
Impact in
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 40
- Multiple Myeloma Research and Treatments 25
- Chronic Myeloid Leukemia Treatments 13
- Acute Myeloid Leukemia Research 6
- Oncology 31
- CAR-T cell therapy research 22
- Co-authors
- Mark C. Johnson (1 shared paper)James H. Moller (1 shared paper)John M. Timmerman (12 shared papers)Monica Mead (14 shared papers)Wendy Stock (3 shared papers)Todd A. Fehniger (4 shared papers)David D. Hurd (4 shared papers)Nancy L. Bartlett (4 shared papers)
- Journals
- Blood (23 papers)Journal of Clinical Oncology (13 papers)Cancer Research (7 papers)HemaSphere (3 papers)Human Vaccines & Immunotherapeutics (2 papers)
- Partner nations
- United StatesCanadaSpain
In The Last Decade
Sarah Larson
68 papers receiving 764 citations
Peers
Comparison fields: 5 of 59
- Hematology 257
- Genetics 162
- Oncology 323
- Pathology and Forensic Medicine 190
- Neurology 69
Countries citing papers authored by Sarah Larson
This map shows the geographic impact of Sarah Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Larson more than expected).
Fields of papers citing papers by Sarah Larson
This network shows the impact of papers produced by Sarah Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Larson. The network helps show where Sarah Larson may publish in the future.
Co-authors
The 25 scholars most cited alongside Sarah Larson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 79 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 137 | |
| 2 | 2019 | 100 | |
| 3 | 2007 | 62 | |
| 4 | 2019 | 45 | |
| 5 | 2020 | 36 | |
| 6 | 2008 | 26 | |
| 7 | 2023 | 25 | |
| 8 | 2017 | 25 | |
| 9 | 2011 | 23 | |
| 10 | 2011 | 21 | |
| 11 | 2018 | 20 | |
| 12 | 2021 | 18 | |
| 13 | 2009 | 17 | |
| 14 | 2023 | 15 | |
| 15 | Effects of acetazolamide on the renal excretion of phosphate in hypoparathyroidism and pseudohypoparathyroidism. | 1977 | 13 |
| 16 | 2012 | 11 | |
| 17 | 2020 | 11 | |
| 18 | A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. | 2021 | 10 |
| 19 | 2021 | 9 | |
| 20 | 2022 | 9 |
About Sarah Larson
Sarah Larson is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Pathology and Forensic Medicine, having authored 79 papers that have together received 775 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (25 papers), CAR-T cell therapy research (22 papers), Chronic Lymphocytic Leukemia Research (18 papers), Chronic Myeloid Leukemia Treatments (13 papers), Lymphoma Diagnosis and Treatment (10 papers), Protein Degradation and Inhibitors (7 papers), Acute Myeloid Leukemia Research (6 papers) and Biosimilars and Bioanalytical Methods (4 papers). The work is most often cited by research in Hematology (257 citations), Genetics (162 citations), Oncology (323 citations), Pathology and Forensic Medicine (190 citations) and Neurology (69 citations). Sarah Larson has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Mark C. Johnson, James H. Moller, John M. Timmerman, Monica Mead, Wendy Stock, Todd A. Fehniger, David D. Hurd, Nancy L. Bartlett, Marilyn J. Siegel and Kathryn Trinkaus. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, HemaSphere and Human Vaccines & Immunotherapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.